Russell Investments Group, Ltd. Crinetics Pharmaceuticals, Inc. Transaction History
Russell Investments Group, Ltd.
- $66.8 Billion
- Q3 2024
A detailed history of Russell Investments Group, Ltd. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 77,701 shares of CRNX stock, worth $4.64 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
77,701
Previous 102,394
24.12%
Holding current value
$4.64 Million
Previous $4.59 Million
13.48%
% of portfolio
0.01%
Previous 0.01%
Shares
12 transactions
Others Institutions Holding CRNX
# of Institutions
240Shares Held
79.5MCall Options Held
23.3KPut Options Held
44.3K-
Vanguard Group Inc Valley Forge, PA6.29MShares$375 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$372 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.89MShares$351 Million2.95% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.94MShares$295 Million0.03% of portfolio
-
Wellington Management Group LLP Boston, MA4.46MShares$266 Million0.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $3.21B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...